Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB-001 PK and Tolerability in Healthy Subjects
NCT05361005Phase 1Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vilobelimab in coronavirus disease 2019 (COVID-19), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and hidradenitis suppurativa (HS), sponsored by Staidson Biopharmaceutical. Primary endpoints: Incidence of Adverse Events at 28 days, Maximum plasma concentration at 504 hours and 7 more. Started Mar 2020; status: completed.
02
Drugs
vilobelimab
03
Conditions
coronavirus disease 2019 (COVID-19)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05361005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361005.